JP2020521456A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020521456A5 JP2020521456A5 JP2019564937A JP2019564937A JP2020521456A5 JP 2020521456 A5 JP2020521456 A5 JP 2020521456A5 JP 2019564937 A JP2019564937 A JP 2019564937A JP 2019564937 A JP2019564937 A JP 2019564937A JP 2020521456 A5 JP2020521456 A5 JP 2020521456A5
- Authority
- JP
- Japan
- Prior art keywords
- item
- polypeptide
- seq
- active fragment
- biologically active
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022166786A JP7450683B2 (ja) | 2017-05-25 | 2022-10-18 | Ｃｂｌｂエンドヌクレアーゼバリアント、組成物、および使用方法 |
| JP2024032998A JP7793669B2 (ja) | 2017-05-25 | 2024-03-05 | Ｃｂｌｂエンドヌクレアーゼバリアント、組成物、および使用方法 |
| JP2025259443A JP2026034640A (ja) | 2017-05-25 | 2025-12-17 | Ｃｂｌｂエンドヌクレアーゼバリアント、組成物、および使用方法 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762511194P | 2017-05-25 | 2017-05-25 | |
| US62/511,194 | 2017-05-25 | ||
| US201762567417P | 2017-10-03 | 2017-10-03 | |
| US62/567,417 | 2017-10-03 | ||
| PCT/US2018/034726 WO2018218194A1 (en) | 2017-05-25 | 2018-05-25 | Cblb endonuclease variants, compositions, and methods of use |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022166786A Division JP7450683B2 (ja) | 2017-05-25 | 2022-10-18 | Ｃｂｌｂエンドヌクレアーゼバリアント、組成物、および使用方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020521456A JP2020521456A (ja) | 2020-07-27 |
| JP2020521456A5 true JP2020521456A5 (https=) | 2021-05-20 |
| JP7191042B2 JP7191042B2 (ja) | 2022-12-16 |
Family
ID=64395994
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019564937A Active JP7191042B2 (ja) | 2017-05-25 | 2018-05-25 | Ｃｂｌｂエンドヌクレアーゼバリアント、組成物、および使用方法 |
| JP2022166786A Active JP7450683B2 (ja) | 2017-05-25 | 2022-10-18 | Ｃｂｌｂエンドヌクレアーゼバリアント、組成物、および使用方法 |
| JP2024032998A Active JP7793669B2 (ja) | 2017-05-25 | 2024-03-05 | Ｃｂｌｂエンドヌクレアーゼバリアント、組成物、および使用方法 |
| JP2025259443A Pending JP2026034640A (ja) | 2017-05-25 | 2025-12-17 | Ｃｂｌｂエンドヌクレアーゼバリアント、組成物、および使用方法 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022166786A Active JP7450683B2 (ja) | 2017-05-25 | 2022-10-18 | Ｃｂｌｂエンドヌクレアーゼバリアント、組成物、および使用方法 |
| JP2024032998A Active JP7793669B2 (ja) | 2017-05-25 | 2024-03-05 | Ｃｂｌｂエンドヌクレアーゼバリアント、組成物、および使用方法 |
| JP2025259443A Pending JP2026034640A (ja) | 2017-05-25 | 2025-12-17 | Ｃｂｌｂエンドヌクレアーゼバリアント、組成物、および使用方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (4) | US12227740B2 (https=) |
| EP (1) | EP3630962A4 (https=) |
| JP (4) | JP7191042B2 (https=) |
| KR (2) | KR102742817B1 (https=) |
| CN (1) | CN110799644A (https=) |
| AU (2) | AU2018273979B2 (https=) |
| CA (1) | CA3064014A1 (https=) |
| IL (2) | IL313037A (https=) |
| MA (1) | MA48797A (https=) |
| MX (1) | MX2019014100A (https=) |
| WO (1) | WO2018218194A1 (https=) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102622910B1 (ko) | 2016-09-08 | 2024-01-10 | 2세븐티 바이오, 인코포레이티드 | Pd-1 호밍 엔도뉴클레아제 변이체, 조성물 및 사용 방법 |
| IL313037A (en) | 2017-05-25 | 2024-07-01 | 2Seventy Bio Inc | Cblb endonuclease variants, compositions, and methods of use |
| JP2021527409A (ja) | 2018-06-14 | 2021-10-14 | ブルーバード バイオ， インコーポレイテッド | Ｃｄ７９ａキメラ抗原受容体 |
| WO2020072059A1 (en) | 2018-10-04 | 2020-04-09 | Bluebird Bio, Inc. | Cblb endonuclease variants, compositions, and methods of use |
| US12577547B2 (en) | 2018-12-10 | 2026-03-17 | Regeneron Pharmaceuticals, Inc. | PDCD-1 homing endonuclease variants |
| WO2020123371A2 (en) * | 2018-12-10 | 2020-06-18 | Bluebird Bio, Inc. | Homing endonuclease variants |
| US20240034768A1 (en) * | 2018-12-14 | 2024-02-01 | 2Seventy Bio, Inc. | Dimerizing agent regulated immunoreceptor complexes |
| US20220280567A1 (en) * | 2019-06-14 | 2022-09-08 | 2Seventy Bio, Inc. | Compositions and methods for treating cancer |
| GB2607514B (en) | 2020-07-20 | 2023-06-21 | Enanta Pharm Inc | Functionalized peptides as antiviral agents |
| US11352363B1 (en) | 2020-11-23 | 2022-06-07 | Enanta Pharmaceuticals, Inc. | Spiropyrrolidine derived antiviral agents |
| US12540141B2 (en) | 2020-11-23 | 2026-02-03 | Enanta Pharmaceuticals, Inc. | Spiropyrrolidine derived antiviral agents |
| KR20230124583A (ko) | 2020-11-23 | 2023-08-25 | 이난타 파마슈티칼스, 인코포레이티드 | 신규한 스피로피롤리딘 유래 항바이러스제 |
| US11384090B2 (en) | 2020-11-23 | 2022-07-12 | Enanta Pharmaceuticals, Inc. | Spiropyrrolidine derived antiviral agents |
| US20240336904A1 (en) * | 2020-12-21 | 2024-10-10 | 2Seventy Bio, Inc. | Compositions and methods for site-directed mutagenesis |
| US11319325B1 (en) | 2021-05-11 | 2022-05-03 | Enanta Pharmaceuticals, Inc. | Macrocyclic spiropyrrolidine derived antiviral agents |
| US11325916B1 (en) | 2021-07-29 | 2022-05-10 | Enanta Pharmaceuticals, Inc. | Spiropyrrolidine derived antiviral agents |
| US11339170B1 (en) | 2021-07-23 | 2022-05-24 | Enanta Pharmaceuticals, Inc. | Spiropyrrolidine derived antiviral agents |
Family Cites Families (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4751180A (en) | 1985-03-28 | 1988-06-14 | Chiron Corporation | Expression using fused genes providing for protein product |
| US4935233A (en) | 1985-12-02 | 1990-06-19 | G. D. Searle And Company | Covalently linked polypeptide cell modulators |
| US4873192A (en) | 1987-02-17 | 1989-10-10 | The United States Of America As Represented By The Department Of Health And Human Services | Process for site specific mutagenesis without phenotypic selection |
| GB8918616D0 (en) | 1989-08-15 | 1989-09-27 | Univ Glasgow | Herpes simplex virus type 1 mutant |
| US5804413A (en) | 1992-07-31 | 1998-09-08 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Herpes simplex virus strains for gene transfer |
| GB9415319D0 (en) | 1994-07-29 | 1994-09-21 | Medical Res Council | HSV viral vector |
| US5846782A (en) | 1995-11-28 | 1998-12-08 | Genvec, Inc. | Targeting adenovirus with use of constrained peptide motifs |
| US6093570A (en) | 1995-06-07 | 2000-07-25 | The University Of North Carolina At Chapel Hill | Helper virus-free AAV production |
| US6013516A (en) | 1995-10-06 | 2000-01-11 | The Salk Institute For Biological Studies | Vector and method of use for nucleic acid delivery to non-dividing cells |
| AU8605598A (en) | 1997-07-31 | 1999-02-22 | University Of Pittsburgh | Targeted hsv vectors |
| US5994136A (en) | 1997-12-12 | 1999-11-30 | Cell Genesys, Inc. | Method and means for producing high titer, safe, recombinant lentivirus vectors |
| FR2777909B1 (fr) | 1998-04-24 | 2002-08-02 | Pasteur Institut | Utilisation de sequences d'adn de structure triplex pour le tranfert de sequences de nucleotides dans des cellules, vecteurs recombinants contenant ces sequences triplex |
| US6692736B2 (en) | 2000-03-24 | 2004-02-17 | Cell Genesys, Inc. | Cell-specific adenovirus vectors comprising an internal ribosome entry site |
| NZ522840A (en) | 2000-06-01 | 2004-12-24 | Univ North Carolina | A parvovirus vector that carries a duplexed genome resulting in co-packaging of strands of plus and minus polarity tethered together |
| WO2009095742A1 (en) | 2008-01-31 | 2009-08-06 | Cellectis | New i-crei derived single-chain meganuclease and uses thereof |
| US20060153826A1 (en) | 2003-01-28 | 2006-07-13 | Sylvain Arnould | Use of meganucleases for inducing homologous recombination ex vivo and in toto in vertebrate somatic tissues and application thereof |
| FR2872170B1 (fr) | 2004-06-25 | 2006-11-10 | Centre Nat Rech Scient Cnrse | Lentivirus non interactif et non replicatif, preparation et utilisations |
| EP1828390B1 (en) | 2004-12-15 | 2012-06-13 | The University Of North Carolina At Chapel Hill | Chimeric vectors |
| EP2215223B1 (en) | 2007-10-31 | 2013-05-01 | Precision Biosciences, Inc. | Rationally-designed single-chain meganucleases with non-palindromic recognition sequences |
| US20110239315A1 (en) | 2009-01-12 | 2011-09-29 | Ulla Bonas | Modular dna-binding domains and methods of use |
| EP2396343B1 (en) | 2009-02-11 | 2017-05-17 | The University of North Carolina At Chapel Hill | Modified virus vectors and methods of making and using the same |
| US20110294217A1 (en) * | 2009-02-12 | 2011-12-01 | Fred Hutchinson Cancer Research Center | Dna nicking enzyme from a homing endonuclease that stimulates site-specific gene conversion |
| US10316304B2 (en) * | 2009-11-27 | 2019-06-11 | Basf Plant Science Company Gmbh | Chimeric endonucleases and uses thereof |
| ES2683695T3 (es) | 2010-01-12 | 2018-09-27 | The University Of North Carolina At Chapel Hill | Repeticiones terminales invertidas restrictivas para vectores virales |
| CA2788682C (en) | 2010-02-05 | 2019-03-05 | The University Of North Carolina At Chapel Hill | Compositions and methods for enhanced parvovirus transduction |
| US20140148361A1 (en) * | 2010-06-07 | 2014-05-29 | Barry L. Stoddard | Generation and Expression of Engineered I-ONUI Endonuclease and Its Homologues and Uses Thereof |
| EP2633040B1 (en) | 2010-10-27 | 2019-07-10 | Cellectis | Method for increasing the efficiency of double-strand break-induced mutagenesis |
| WO2012118717A2 (en) | 2011-02-28 | 2012-09-07 | Seattle Children's Research Institute | Coupling endonucleases with end-processing enzymes drive high efficiency gene disruption |
| EP2694089B1 (en) | 2011-04-05 | 2024-06-05 | Cellectis | New tale-protein scaffolds and uses thereof |
| EP2718432A4 (en) | 2011-06-10 | 2015-01-07 | Basf Plant Science Co Gmbh | NUCLEASE FUSION PROTEIN AND USES THEREOF |
| US8450107B1 (en) | 2011-11-30 | 2013-05-28 | The Broad Institute Inc. | Nucleotide-specific recognition sequences for designer TAL effectors |
| ES2883131T3 (es) | 2013-05-29 | 2021-12-07 | Cellectis | Métodos para la modificación de células T para inmunoterapia utilizando el sistema de nucleasa CAS guiado por ARN |
| JP6488283B2 (ja) * | 2013-05-31 | 2019-03-20 | セレクティスＣｅｌｌｅｃｔｉｓ | Ｃ−ｃケモカイン受容体５型（ｃｃｒ５）遺伝子を開裂するｌａｇｌｉｄａｄｇホーミングエンドヌクレアーゼおよびその用途 |
| US10000746B2 (en) * | 2013-05-31 | 2018-06-19 | Cellectis | LAGLIDADG homing endonuclease cleaving the T cell receptor alpha gene and uses thereof |
| CA2945335A1 (en) | 2014-04-18 | 2015-10-22 | Editas Medicine, Inc. | Crispr-cas-related methods, compositions and components for cancer immunotherapy |
| US9790490B2 (en) * | 2015-06-18 | 2017-10-17 | The Broad Institute Inc. | CRISPR enzymes and systems |
| EP4043556B1 (en) | 2015-06-30 | 2024-02-07 | Cellectis | Methods for improving functionality in nk cell by gene inactivation using specific endonuclease |
| JP2019525759A (ja) | 2016-07-25 | 2019-09-12 | ブルーバード バイオ， インコーポレイテッド | Ｂｃｌ１１ａホーミングエンドヌクレアーゼバリアント、組成物、および使用方法 |
| WO2018035141A1 (en) | 2016-08-16 | 2018-02-22 | Bluebird Bio, Inc. | Il-10 receptor alpha homing endonuclease variants, compositions, and methods of use |
| WO2018039333A1 (en) | 2016-08-23 | 2018-03-01 | Bluebird Bio, Inc. | Tim3 homing endonuclease variants, compositions, and methods of use |
| KR102622910B1 (ko) | 2016-09-08 | 2024-01-10 | 2세븐티 바이오, 인코포레이티드 | Pd-1 호밍 엔도뉴클레아제 변이체, 조성물 및 사용 방법 |
| IL313037A (en) | 2017-05-25 | 2024-07-01 | 2Seventy Bio Inc | Cblb endonuclease variants, compositions, and methods of use |
| WO2020072059A1 (en) | 2018-10-04 | 2020-04-09 | Bluebird Bio, Inc. | Cblb endonuclease variants, compositions, and methods of use |
-
2018
- 2018-05-25 IL IL313037A patent/IL313037A/en unknown
- 2018-05-25 CA CA3064014A patent/CA3064014A1/en active Pending
- 2018-05-25 US US16/616,713 patent/US12227740B2/en active Active
- 2018-05-25 CN CN201880042211.8A patent/CN110799644A/zh active Pending
- 2018-05-25 JP JP2019564937A patent/JP7191042B2/ja active Active
- 2018-05-25 WO PCT/US2018/034726 patent/WO2018218194A1/en not_active Ceased
- 2018-05-25 IL IL270776A patent/IL270776B2/en unknown
- 2018-05-25 KR KR1020237034961A patent/KR102742817B1/ko active Active
- 2018-05-25 KR KR1020197036681A patent/KR102590466B1/ko active Active
- 2018-05-25 AU AU2018273979A patent/AU2018273979B2/en not_active Expired - Fee Related
- 2018-05-25 MX MX2019014100A patent/MX2019014100A/es unknown
- 2018-05-25 MA MA048797A patent/MA48797A/fr unknown
- 2018-05-25 EP EP18806825.8A patent/EP3630962A4/en active Pending
-
2019
- 2019-11-25 US US16/694,815 patent/US10927367B2/en active Active
-
2021
- 2021-01-15 US US17/150,293 patent/US11732255B2/en active Active
-
2022
- 2022-10-18 JP JP2022166786A patent/JP7450683B2/ja active Active
-
2024
- 2024-03-05 JP JP2024032998A patent/JP7793669B2/ja active Active
-
2025
- 2025-01-16 AU AU2025200323A patent/AU2025200323B2/en active Active
- 2025-02-13 US US19/052,367 patent/US20250179469A1/en active Pending
- 2025-12-17 JP JP2025259443A patent/JP2026034640A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020521456A5 (https=) | ||
| JP2019526268A5 (https=) | ||
| JP2019535240A5 (https=) | ||
| JP6748105B2 (ja) | がん治療のための遺伝子改変ｎｋ−９２細胞およびモノクローナル抗体 | |
| JP7191042B2 (ja) | Ｃｂｌｂエンドヌクレアーゼバリアント、組成物、および使用方法 | |
| CN112585277A (zh) | 表达重组受体的t细胞、相关多核苷酸和方法 | |
| US20210309713A1 (en) | Chimeric Antigen Receptor and Method for Treating Cancers | |
| CN113412276A (zh) | 二聚化剂调节的免疫受体复合物 | |
| KR20160105882A (ko) | 신규한 합성 생물학에 기반한 adcc 기술 | |
| KR20220031549A (ko) | Cll-1 표적화 면역요법 | |
| KR20200108285A (ko) | Nkg2d daric 수용체 | |
| KR20200110326A (ko) | Daric 인터류킨 수용체 | |
| Stärck et al. | Immunotherapy with TCR-redirected T cells: comparison of TCR-transduced and TCR-engineered hematopoietic stem cell–derived T cells | |
| CA3224974A1 (en) | Polycistronic vectors for cell-based therapies | |
| JPWO2022216915A5 (https=) | ||
| Plougastel et al. | Sequence Analysis of a 62-kb Region Overlapping the HumanKLRCCluster of Genes | |
| CN116997654A (zh) | 编码抗乙酰胆碱受体自身抗体的嵌合受体的基因 | |
| EP3914719A1 (en) | Cell-specific transcriptional regulatory sequences and uses thereof | |
| US6790614B1 (en) | Selectable cell surface marker genes | |
| CN116802203A (zh) | 从经修饰的恒定cd3免疫球蛋白超家族链基因座表达嵌合受体的细胞、相关多核苷酸和方法 | |
| RU2019110065A (ru) | Варианты, композиции и методы применения хоминг-эндонуклеазы pd-1 | |
| AU779462B2 (en) | Selectable cell surface marker genes | |
| Ibach | Adoptive T-cell Therapy via Chimeric Antigen Receptors (Cars) against Leukemia in Combination with A Human Suicide Gene | |
| AU2024316791A1 (en) | Chimeric ilt receptor compositions and methods | |
| WO2025179057A1 (en) | In vivo modification of cell genomes |